Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9MW2921 in Advanced Solid Tumors
NCT05990452Phase 2Active, not recruiting
- Sponsor
- Mabwell
- Start
- Aug 2023
- Primary completion
- Sep 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of 9MW2921 in solid tumor (advanced stage), sponsored by Mabwell. Started Aug 2023; status: active, not recruiting.
02
Drugs
9MW2921
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05990452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05990452.